Partnership Objective
To advance treatments for degenerative retinal diseases through a large-scale academic-industry collaboration supported by cost-shared investment.
Trinity Added Value
- Strong biomedical research expertise in ophthalmology and neuroscience.
- Capability to host multi-year PhD and PDRA projects under state-industry programmes.
- Proven leadership in strategic health partnerships and coordination of diverse industry stakeholders.
Partnership Activities and Approach
- €3.2M cost-shared programme with multiple pharma and biotech partners.
- Funding supports long-term research posts and provides institutional overheads.
- Inclusive model allowing non-Enterprise Ireland and international partners.
Impact
Drives innovation in retinal disease treatment, positions Trinity as a central hub in vision research, and strengthens industry-academic collaboration in Ireland and beyond.